Burkholderia pseudomallei: Public Health and Occupational Risk of Exposure due to an Imported Case of Melioidosis

Nawal Al-Kindi^1, , Paraj Hasmukhbhai Shah², Naryan A³, Seif Al-Abri⁴ and Amina Al Jardani¹

¹Central Public Health Laboratory, Darsait, Muscat, Oman

²Communicable Disease Surveillance & Control, North Sharqiya

³Ibra Hospital, Ministry of Health, Oman

⁴Directorate General for Disease Surveillance & Control Ministry of Health, Oman

Cite this paper

Nawal Al-Kindi, Paraj Hasmukhbhai Shah, Naryan A, Seif Al-Abri and Amina Al Jardani. Burkholderia pseudomallei: Public Health and Occupational Risk of Exposure due to an Imported Case of Melioidosis. American Journal of Medical Case Reports. 2019; 7(11):292-296. doi: 10.12691/AJMCR-7-11-8

Abstract

We describe the case of a 47 years old Sri Lankan man living in Oman with melioidosis and the resultant occupational risk of exposure to 5 laboratory staff members to the causative agent, Burkholderia pseudomallei. Widely reported as an endemic disease in tropical and subtropical areas, B. pseudomallei was imported to Oman by our patient who had risk factors of diabetes mellitus and alcoholic cirrhotic liver disease. Microbiological and biochemical tests identified the gram negative bacillus, B. pseudomallei, in the patient’s blood sample. Five laboratory workers had occupational exposure to Burkholderia pseudomallei and received post-exposure prophylaxis. Our report highlights the importance of early suspicion of the infection and managing the patient with the correct international protocols for melioidosis especially for patients with severe sepsis and septic shock in the Intensive Care Unit (ICU). Furthermore, the importance of increased awareness among laboratory personnel and the need for good laboratory practices is reported. Furthermore, improved surveillance is essential to guide early diagnosis and prompt treatment.

Keywords

Burkholderia pseudomallei, melioidosis, occupational risk

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Limmathurotsakul D, Golding N, Dance DA, Messina JP, Pigott DM, Moyes CL, et al. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat Microbiol. 2016; 1: 15008.
[2]	Currie BJ. Melioidosis: evolving concepts in epidemiology, pathogenesis and treatment. Semin Respir Crit Care Med. 2015; 36: 111-25.
[3]	Dance DA. Melioidosis: the tip of the iceberg? Clin Microbiol Rev. 1991; 4: 52-60.
[4]	Currie BJ, Fisher DA, Howard DM, Burrow JNC, Selvanayagam S, Snelling PL, et al. The epidemiology of melioidosis in Australia and Papua New Guinea. Acta Trop. 2000; 74(2-3): 121-7.
[5]	Suputtamongkol Y, Hall AJ, Dance DA, Chaowagul W, Rajchanuvong A, Smith MD, et al. The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol 1994a Oct; 23(5): 1082-1090.
[6]	Benoit TJ, Blaney DD, Doker TJ, Gee JE, Elrod MG, Rolim DB, et al. Review Article: A Review of Melioidosis Cases in the Americas. Am J Trop Med Hyg 2015; 93(6): 1134-9.
[7]	AL Tamtami N, Khamis F, Al-Jardani. Imported case of melioidosis in Oman: Case report. Oman Med J 2017; 32(1): 62-5.
[8]	Limmathurotsakul D, Peacock SJ. Melioidosis: A clinical overview. Br Med Bull 2011; 99(1): 125-139.
[9]	Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 2010; 4(11): e900.
[10]	Athan E, Allworth AM, Engler C, Bastian I, Cheng AC. Melioidosis in Tsunami Survivors. Emerg Infect Dis. 2005; 11: 1638-9.
[11]	Limmathurotsakul, D. et al. Increasing incidence of human melioidosis in northeast Thailand. Am. J. Trop. Med. Hyg .2010; 82: 1113-1117.
[12]	Muthusamy KA, Waran V, Puthucheary SD. Spectra of central nervous system melioidosis. J Clin Neurosci. 2007; 14: 1213-5.
[13]	Cheng AC, Currie BJ, Dance DA, Funnell SG, Limmathurotsakul D, Simpson AJ, et al. Clinical definitions of melioidosis. Am J Trop Med Hyg 2013; 88(3): 411-413.
[14]	Vidyalakshmi K, Lipika S, Vishal S, et al. Emerging clinicoepidemiological trends in melioidosis: analysis of 95 cases from western coastal India. Int J Infect Dis. 2012; 16: e491-e497
[15]	Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev. 2005; 18: 383-416.
[16]	World Health Organization WHO biosafety manual. Geneva (Switzerland): The Organization; 2003. [cited 2008 May 20]. http://www.who.int/csr/resources/publications/biosafety/who_cds_csr_lyo_2004_11/en.
[17]	Lipsitz R, Garges S, Aurigemma R, Baccam P, Blaney DD, Cheng AC et al. Workshop on Treatment of and Postexposure Prophylaxis for Burkholderia pseudomallei and B. mallei Infection 2010; 18, e2 (2012).
[18]	Peacock SJ, Schweizer HP, Dance DAB, Smith TL, Gee JE, Wuthiekanun V, Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg Infect Dis. 2008; 14: e2.
[19]	Sivalingam SP, Sim SH, Jasper LC, Wang D, Liu Y, Ooi EE. Pre- and post-exposure prophyalxis of experimental Burkholderia pseudomallei infection with doxycycline, amoxicillin/calvulanic acid and co-trimoxazole. J Antimicrob Chemother. 2008; 61: 674-8.
[20]	Atkins T, Prior R, Mack K, Russell P, Nelson M, Oyston P, Dougan G, Titball R. A mutant of Burkholderia pseudomallei, auxotrophic in the branched chain amino acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis. Infect Immun 2002; 70(9): 5290-4.
[21]	Peacock SJ, Limmathurotsakul D, Lubell Y, Koh GC, White LJ, Day NP, Titball RW. Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PLoS Neglect Trop Dis 2012; 6(1): e1488.